Journal Article

Effective Suppression of Vancomycin-Resistant <i>Enterococcus</i> Species in Asymptomatic Gastrointestinal Carriers by a Novel Glycolipodepsipeptide, Ramoplanin

Michael T. Wong, Carol A. Kauffman, Harold C. Standiford, Peter Linden, Glenn Fort, Henry J. Fuchs, Steven B. Porter and Richard P. Wenzel

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue 9, pages 1476-1482
Published in print November 2001 | ISSN: 1058-4838
Published online November 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/322687
Effective Suppression of Vancomycin-Resistant Enterococcus Species in Asymptomatic Gastrointestinal Carriers by a Novel Glycolipodepsipeptide, Ramoplanin

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Nosocomial bloodstream infections due to vancomycin-resistant enterococci (VRE) are associated with increased morbidity rates, mortality rates, and hospitalization costs. Gastrointestinal carriage of VRE is an important risk factor for subsequent infections. This 3-arm, phase II, double-blinded, randomized, multicenter, placebo-controlled study evaluated the safety and efficacy of oral ramoplanin (a novel, nonabsorbed glycolipodepsipeptide) versus placebo for suppression of gastrointestinal VRE colonization. Sixty-eight patients who were colonized with VRE were enrolled and received 2 daily doses of ramoplanin (100 mg or 400 mg) or placebo orally for 7 days. The primary end point was the proportion of persons per group from whom VRE were not recovered (VRE-free) on days 7, 14, and 21 after screening. After treatment, VRE-free status was as follows: day 7, none of the 20 patients in the placebo group, and 17 of 21 (P < .001) and 18 of 20 (P < .001) in the 100-mg and 400-mg ramoplanin groups, respectively; on day 14, 2 of 20 patients in the placebo group, and 6 of 21 (P = .134) and 7 of 17 (P = .028), in the 100-mg and 400-mg ramoplanin groups, respectively. By day 21, there were no differences between treatment groups. Adverse events were similar for all treatment groups. Ramoplanin was safe and effective in temporarily suppressing gastrointestinal VRE carriage.

Journal Article.  4410 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.